ATXN3

Across TCGA pan-cancer cohorts, ATXN3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ATXN3 data layer compared with 21 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ATXN3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ATXN3 expression acts as an unfavorable survival marker.

HNSC, COAD, and CHOL are the cancer types where ATXN3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.222	0.710	.031	6	view →
COAD	OS	Median	II,III,IV	0.168	0.788	.005	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ATXN3–HNSC (OS)

Open the HNSC breakdown →